In conjunction with the publication of the interim report for the first quarter of 2022, Isofol invites investors, analysts, and media to an audiocast on May 12, 2022 at 11:00 a.m. CEST. The presentation will be held by Isofol´s CEO Ulf Jungnelius and CFO Gustaf Albèrt, who will present and comment the report, followed by a Q&A-session. The presentation will be held in English.
Date and time
May 12, 2022, at 11:00 a.m. CEST
Webcast link
https://tv.streamfabriken.com/isofol-medical-q1-2022
Phone number
To participate via telephone, please dial one of the numbers below.
SE: +46 8 50 55 83 53
UK: +44 333 300 92 68
US: +1 631 913 1422 PIN: 80079640#
The presentation will also be available on Isofol’s website after the broadcast:
https://isofolmedical.com/company-presentations/
For further information, please contact
Isofol Medical AB (publ)
Ulf Jungnelius, M.D., Chief Executive Officer
E-mail: jungnelius@isofolmedical.com
Phone: +46 (0) 709 16 89 55
Gustaf Albèrt, CFO
E-mail: gustaf.albert@isofolmedical.com
Phone: +46 (0)709 16 83 02
The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CEST on May 3, 2022.
About Isofol Medical AB (publ)
Isofol Medical AB (publ) is a clinical stage biotech company developing arfolitixorin to improve the efficacy of standard of care chemotherapy for advanced colorectal cancer by increasing tumor response and progression free survival. Isofol holds a worldwide exclusive license agreement with Merck & Cie, Darmstadt, Germany to develop and commercialize arfolitixorin for oncology indications. Isofol Medical AB (publ) is traded on the Nasdaq Stockholm.
